logo
STEMCELL Technologies Announces Acquisition of Cellular Highways

STEMCELL Technologies Announces Acquisition of Cellular Highways

Business Wire02-06-2025

VANCOUVER, British Columbia & CAMBRIDGE, England--(BUSINESS WIRE)--STEMCELL Technologies, Canada's largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.
The acquisition includes the revolutionary Highway1 instrument, which uses Cellular Highways' proprietary VACS™ (Vortex-Actuated Cell Sorting) technology. VACS™ gently and precisely sorts cells and enables high-speed cell sorting in a closed, sterile system through microfluidic vortices. VACS™ uniquely avoids traditional non-sterile droplet-based and electrostatic sorting methods, which can degrade cell health and viability. Highway1 enables researchers and cell therapy developers to process cells more efficiently while maintaining high cell integrity for sensitive applications in research and therapeutic development. This significantly reduces the timelines and costs for research and development.
'Since entering the market in 2024, Highway1 has proven to be the fastest GMP-ready cell sorter available and is designed and manufactured under ISO 13485 certification. We are pleased to welcome this powerful instrument, along with the entire Cellular Highways platform, to STEMCELL's portfolio of advanced cell processing instruments," said Dr. Allen Eaves, President and CEO, STEMCELL. 'With this new complement to our existing cell isolation and culture product lines, we look forward to further supporting scientists with the tools they need to accelerate innovation in the development of life-changing cell and gene therapies.'
Current Highway1 customers will receive continued technical support from STEMCELL's dedicated team of Product and Scientific Support specialists.
'Cellular Highways customers are in great hands with STEMCELL—a major player in the global biotechnology industry with a stellar reputation for its best-in-class products and customer service,' said Dr. Alex Jones on behalf of Cellular Highways. 'With STEMCELL's global reach, we are excited that this acquisition will help introduce Highway1 to even more labs around the world.'
'The acquisition is a testament to Cellular Highways' exceptional team and innovation. With STEMCELL's reputation and global reach, it is ideally positioned to thrive in the rapidly growing research and cell therapy manufacturing markets,' said Dr. Sam Hyde, CEO of TTP. 'For TTP Group, this demonstrates our unique ability to build and nurture businesses that deliver breakthrough technologies, transform them into market-leading products, and create significant value.'
'This acquisition aligns with STEMCELL's strategic growth in the cell therapy space,' said Dr. Eaves. 'With this enhanced ability to support cutting-edge research and biomanufacturing workflows, we will continue to help the scientific community advance research and make discoveries with greater speed and accuracy.'
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
About TTP Group
TTP Group is an independent technology company where scientists and engineers collaborate to invent, design, and engineer breakthrough technologies and products. Working across sectors including healthcare, life sciences, communications, and industrials, TTP combines deep technical expertise with commercial insight to deliver innovations that drive progress and create value. Founded in 1987, TTP Group develops technologies and products for clients worldwide and nurtures high-impact venture businesses.
About Cellular Highways
Cellular Highways was founded to take fluorescence-based cell sorting into new therapy development and research applications, requiring fast, gentle, sterile, scalable cell sorting, using the unique potential of the VACS™ technology. Cellular Highways span out from TTP Group.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries

Business Wire

time3 days ago

  • Business Wire

STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries

VANCOUVER, British Columbia--(BUSINESS WIRE)--To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System —a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. 'Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this manual process demands significant time and effort and can lead to inconsistent results,' said Dr. Allen Eaves, President and CEO, STEMCELL. 'With efficient and consistent tissue processing, STEMprep™ helps researchers to work smarter and improve data accuracy, leading to accelerated scientific discoveries.' STEMprep™ ensures efficient, reproducible, and high-yield single-cell suspensions from a wide range of solid tissues while preserving cell functionality and integrity, which is critical for accurate cell isolation and analysis. Researchers can run validated STEMCELL protocols or customize workflows for a range of tissue types and experiments. 'As Scientists Helping Scientists, we are excited to provide a solution that allows flexibility and scalability in support of scientific progress and discovery,' said Dr. Eaves. 'We hope every lab involved with tissue research will embrace the STEMprep™ instrument to optimize their time as they work toward their achievements.' For more information about the STEMprep™ Tissue Dissociator System, please visit STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

Limited-time 4th of July steals: Save on Amazon's most-loved beach bags
Limited-time 4th of July steals: Save on Amazon's most-loved beach bags

USA Today

time3 days ago

  • USA Today

Limited-time 4th of July steals: Save on Amazon's most-loved beach bags

Shop these popular early Prime Day deals just in time for summer fun at the beach! Fourth of July will be here before you know it. No matter your long weekend plans—whether you're beachside, lakeside or just taking in a fireworks show from home—now's the perfect time to shop (and save on) all the essentials that are sure to make your 4th of July sparkle. The item we're most coveting ahead of the holiday? Fourth of July-ready beach bags, which just so happen to be marked down at Amazon right now. From insulated beach bags that double as great coolers to mesh beach bags that'll help keep sticky sand at bay, Amazon's best-selling beach bags are all on sale for up to 50% off as part of the retailer's early Prime Day deals. Don't wait—scoop up summer's most coveted accessory at a fraction of its usual cost, and shop the top Amazon beach bags (each with over 1,000 five-star reviews) below: Early Amazon Prime Day deals: Beach bags on sale Amazon Prime Day 2025 begins on Tuesday, July 8 and will end on Friday, July 11. USA TODAY Shopping will be covering all the savings throughout Prime Day 2025, so be sure tosign up for text alerts,sign up for our newsletter andfollow us on Instagram to stay updated! Our team of savvy editors independently handpicks all recommendations. If you purchase through our links, the USA Today Network may earn a commission. Prices were accurate at the time of publication but may change.

ForSight Robotics raises $125M for cataract surgery platform
ForSight Robotics raises $125M for cataract surgery platform

Yahoo

time4 days ago

  • Yahoo

ForSight Robotics raises $125M for cataract surgery platform

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. ForSight Robotics has raised $125 million as it prepares for first-in-human robotic cataract surgery clinical trials this year. The Israel-based company said this week the funds will support the next phase of growth in the development of its Oryom platform, the world's first robotic surgery platform for cataracts and other eye diseases. Participants in the Series B funding round include Eclipse, Intuitive Surgical co-founder Fred Moll, Adani Group and Reiya Ventures, among other investors. ForSight is scaling up, having identified a need to expand patient access to eye surgery amid a declining number of ophthalmologists and growing demand for vision treatment. The company cited a forecast from researchers at Vanderbilt University pointing to a 12% decline in ophthalmologists by 2035, alongside a projected 24% increase in demand. Joseph Nathan, ForSight co-founder and chief medical officer, said in a statement that the urgent global need presents an 'immense' opportunity for the company. 'We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical,' said Nathan. Starting with cataract surgery, ForSight's platform aims to offer surgeons the dexterity, maneuverability and ergonomics to provide precise and consistent ophthalmic procedures, according to the company. The platform is designed to allow surgeons to navigate complex angles to reach any point in the eye, enabling glaucoma and retinal surgical treatment. 'The company is tapping into a massive, underserved market,' said Eclipse partner Seth Winterroth. ForSight said more than two dozen ophthalmic surgeons have successfully completed hundreds of procedures on animal eye models using its platform. In February, it received ISO 13485:2016 certification, an international benchmark for quality management systems in the medical device industry. The company completed a $55 million funding round in 2022, and has raised a total of $195 million to date. Recommended Reading 4 robotic surgery trends to watch in 2025 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store